In a report involving 318 RA patients, a panel of 12 peripheral blood biomarkers including IL-6, TNF-α, MMP-1 and MMP-3 levels failed to correlate with standard disease activity scales (DAS 28-CRP, RAPID-3, CDAI) or predict responsiveness to abatacept or adalimumab [33]. This evidence concerns the gene MMP3 and rheumatoid arthritis.